EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative study of Japanese nationwide epidemiological studies of myasthenia gravis using datasets of 2006 and 2018

Hiroaki Yoshikawa iD, Yumi Adachi, Yosikazu Nakamura, Nagato Kuriyama, Hiroyuki Murai, Yoshiko Nomura, Yasunari Sakai iD, Kazuo Iwasa, Yutaka Furukawa, Makoto Matsui, Satoshi Kuwabara, Taskforce of Research that Aims to Contribute to Improving the Medical Level of Intractable Diseases and Neuroimmune Patients’ Quality of Life

PLOS One · 2025

DOI: 10.1371/journal.pone.0334041 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Hiroaki Yoshikawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Health Service Center, Kanazawa University, Kanazawa, Ishikawa, Japan. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to identify changes in the clinical presentation and treatment patterns of myasthenia gravis (MG) in Japan by comparing data from nationwide epidemiological surveys conducted in 2006 and 2018.

Methods

We analyzed data from nationwide epidemiological surveys of MG performed across Japan in 2006 (n = 729) and 2018 (n = 1,357). Both surveys adhered to the Survey Manual of Study on Continuous Epidemiological Data Collection of Intractable Diseases established by the Ministry of Health, Labour, and Welfare. We compared the following variables between the two-time points: age of onset, gender distribution, initial symptoms, anti-acetylcholine receptor antibody (AChRAb) status, physiological test results (repetitive nerve stimulation test, edrophonium test), Myasthenia Gravis Foundation of America (MGFA) Clinical Classification, Myasthenia Gravis Activities of Daily Living Profile (MG-ADL) score, and treatment modalities.

Results

Our analysis revealed a significantly older age of onset in the 2018 cohort compared to 2006. The MGFA Clinical Classification was higher in 2018, and bulbar weakness was more frequently reported as an initial symptom. Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. In contrast, the rates of thymectomy and both maximum and current oral steroid dosages decreased during this period.

Conclusion

These findings underscore notable shifts in the clinical characteristics and, particularly, the treatment strategies for MG in Japan over the twelve-year interval. This information is crucial for informing future patient care protocols and healthcare policy development in the management of MG. We emphasize the importance of conducting regular nationwide epidemiological surveys to monitor the evolving landscape of MG and its treatment continuously.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisHumansJapanFemaleMaleMiddle AgedAdultAgedActivities of Daily LivingAdolescentAge of OnsetYoung AdultChildAged, 80 and overImmunoglobulins, IntravenousPlasma ExchangeEast Asian People

Substanzen

Immunoglobulins, Intravenous

Autor:innen und Institutionen

  • Health Service Center, Kanazawa University, Kanazawa, Ishikawa, Japan.
  • Public Health Center, Utsunomiya City, Tochigi, Japan.
  • Shizuoka Graduate University of Public Health, Shizuoka City, Shizuoka, Japan.
  • Department of Neurology, School of Medicine, International University of Health and Welfare, Narita, Chiba, Japan.
  • Yoshiko Nomura Neurological Clinic for Children, Bunkyo-ku, Tokyo, Japan.
  • Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

ORCID-Profile: Hiroaki Yoshikawa, Yasunari Sakai

Förderung

  • Ministry of Health, Labour and Welfare

Zitieren

APA

Yoshikawa, H., Adachi, Y., Nakamura, Y., Kuriyama, N., Murai, H., Nomura, Y., Sakai, Y., Iwasa, K., Furukawa, Y., Matsui, M., Kuwabara, S., & Taskforce of Research that Aims to Contribute to Improving the Medical Level of Intractable Diseases and Neuroimmune Patients’ Quality of Life (2025). Comparative study of Japanese nationwide epidemiological studies of myasthenia gravis using datasets of 2006 and 2018. PLOS One. https://doi.org/10.1371/journal.pone.0334041

Vancouver

Yoshikawa H, Adachi Y, Nakamura Y, Kuriyama N, Murai H, Nomura Y, et al. Comparative study of Japanese nationwide epidemiological studies of myasthenia gravis using datasets of 2006 and 2018. PLOS One. 2025. doi:10.1371/journal.pone.0334041

BibTeX
@article{Yoshikawa2025,
  author = {Yoshikawa, Hiroaki and Adachi, Yumi and Nakamura, Yosikazu and Kuriyama, Nagato and Murai, Hiroyuki and Nomura, Yoshiko and Sakai, Yasunari and Iwasa, Kazuo and Furukawa, Yutaka and Matsui, Makoto and Kuwabara, Satoshi and Taskforce of Research that Aims to Contribute to Improving the Medical Level of Intractable Diseases and Neuroimmune Patients’ Quality of Life, Taskforce of Research that Aims to Contribute to Improving the Medical Level of Intractable Diseases and Neuroimmune Patients’ Quality of Life},
  title = {Comparative study of Japanese nationwide epidemiological studies of myasthenia gravis using datasets of 2006 and 2018},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0334041}
}
Kostenlos starten →